Hematologic Neoplasms

"Hematologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.

Descriptor ID	D019337
MeSH Number(s)	C04.588.448 C15.378.400
Concept/Terms	Hematologic Neoplasms Hematologic Neoplasms Hematologic Malignancy Neoplasms, Hematologic Hematologic Neoplasm Neoplasm, Hematologic Hematological Neoplasms Hematological Neoplasm Neoplasm, Hematological Neoplasms, Hematological Malignancies, Hematologic Malignancy, Hematologic Hematologic Malignancies Hematological Malignancies Hematological Malignancy Malignancies, Hematological Malignancy, Hematological Hematopoietic Neoplasms Hematopoietic Neoplasms Neoplasms, Hematopoietic Hematopoietic Neoplasm Neoplasm, Hematopoietic Hematopoietic Malignancies Hematopoietic Malignancy Malignancies, Hematopoietic Malignancy, Hematopoietic

Below are MeSH descriptors whose meaning is more general than "Hematologic Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Hematologic Neoplasms".

Hematologic Neoplasms
Bone Marrow Neoplasms

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hematologic Neoplasms" by people in this website by year, and whether "Hematologic Neoplasms" was a major or minor topic of these publications.

Bar chart showing 14 publications over 12 distinct years, with a maximum of 2 publications in 2019 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2006	0	1	1
2010	0	1	1
2012	1	0	1
2015	1	0	1
2017	0	1	1
2018	1	0	1
2019	1	1	2
2021	2	0	2
2022	1	0	1
2023	1	0	1
2024	1	0	1

Below are the most recent publications written about "Hematologic Neoplasms" by people in Profiles.

Acanda De La Rocha AM, Berlow NE, Fader M, Coats ER, Saghira C, Espinal PS, Galano J, Khatib Z, Abdella H, Maher OM, Vorontsova Y, Andrade-Feraud CM, Daccache A, Jacome A, Reis V, Holcomb B, Ghurani Y, Rimblas L, Guilarte TR, Hu N, Salyakina D, Azzam DJ. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nat Med. 2024 Apr; 30(4):990-1000.

View in: PubMed
Rodriguez Moncivais OJ, Chavez SA, Estrada Jimenez VH, Sun S, Li L, Kirken RA, Rodriguez G. Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies. Int J Mol Sci. 2023 Sep 26; 24(19).

View in: PubMed
Kekre N, Hay KA, Webb JR, Mallick R, Balasundaram M, Sigrist MK, Clement AM, Nielsen JS, Quizi J, Yung E, Brown SD, Dreolini L, Waller DD, Smazynski J, Gierc NS, Loveless BC, Clark K, Dyer T, Hogg R, McCormick L, Gignac M, Bell S, Chapman DM, Bond D, Yong S, Fung R, Lockyer HM, Hodgson V, Murphy C, Subramanian A, Wiebe E, Yoganathan P, Medynski L, Vaillan DC, Black A, McDiarmid S, Kennah M, Hamelin L, Song K, Narayanan S, Rodrigo JA, Dupont S, Hawrysh T, Presseau J, Thavorn K, Lalu MM, Fergusson DA, Bell JC, Atkins H, Nelson BH, Holt RA. CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Front Immunol. 2022; 13:1074740.

View in: PubMed
Lopez-Candales A, Mathur P, Mounsey JP, Veeraputhiran M. Is heart rate in post-hematopoietic stem cell transplant patients clinically relevant? Postgrad Med. 2022 Jan; 134(1):7-10.

View in: PubMed
Chen Z, Cheng Y, DeRemer D, Diaby V. Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct; 21(5):923-941.

View in: PubMed
De Pascale MR, Belsito A, Sommese L, Signoriello S, Sorriento A, Vasco M, Schiano C, Fiorito C, Durevole G, Casale M, Perrotta S, Casale F, Alfano R, Benincasa G, Nicoletti GF, Napoli C. Blood transfusions and adverse acute events: a retrospective study from 214 transfusion-dependent pediatric patients comparing transfused blood components by apheresis or by whole blood. Ann Ist Super Sanita. 2019 Oct-Dec; 55(4):351-356.

View in: PubMed
Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, Gill S. Bispecific Antibodies in the Treatment of Hematologic Malignancies. Clin Pharmacol Ther. 2019 10; 106(4):781-791.

View in: PubMed
Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, Lalu MM. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2019 04; 33(2):98-110.

View in: PubMed
Sun W, Liu H, Kim Y, Karras N, Pawlowska A, Toomey D, Kyono W, Gaynon P, Rosenthal J, Stein A. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. J Hematol Oncol. 2018 05 02; 11(1):61.

View in: PubMed
Grigor EJM, Fergusson DA, Haggar F, Kekre N, Atkins H, Shorr R, Holt RA, Hutton B, Ramsay T, Seftel M, Jonker D, Daugaard M, Thavorn K, Presseau J, Lalu MM. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. BMJ Open. 2017 12 29; 7(12):e019321.

View in: PubMed

People

Explore

Similar Concepts

Top Journals